2 weeks Ago By Jung So-yeon
CorelineSoft, a global medical AI solution provider, is taking aggressive steps to solidify its position in the U.S. healthcare AI market.
In addition to partnering with major U.S. healthcare organizations, the company is leveraging its cutting-edge AI-powered diagnostic solutions to accelerate its market penetration.
Of particular note is the recent agreement with UMass Memorial Medical Center (UMass) in Massachusetts, which represents a strategic expansion for CoreLinesoft in the U.S. market.
CorelineSoft will be showcasing its core products at the upcoming North American Society for Cardiovascular Imaging (NASCI 2024) in Boston, Massachusetts from September 21-24. The North American Society of Cardiovascular Imaging is the preeminent meeting in the field of heart disease, where global medical imaging experts share the latest technology and clinical practices. At the conference, CorelineSoft will demonstrate AI diagnostic solutions for lung cancer, chronic obstructive pulmonary disease (COPD), and cardiovascular disease.
CorelineSoft's flagship product, AIVEW LCS Plus, is an innovative solution that enables simultaneous analysis of multiple diseases such as lung cancer, emphysema, and coronary artery disease in a single chest CT scan. The product is being used in various global lung cancer screening projects organized by the European Union, Germany, Italy, and other countries, making a significant contribution to patient care through early detection of the disease. AVIEW CAC, an AI cardiovascular diagnosis solution, will also be showcased at the conference.
AVIEW CAC provides the ability to automatically analyze and quantify image data from computed tomography (CT) scans, which can significantly reduce reading time. Studies have shown that AI can reduce the time it takes to read images by approximately 60%. The UMass deal is strategic for CorelineSoft to gain traction in the U.
S. market. UMass is one of the top five hospitals in Massachusetts and has been using CorelineSoft's key products since the beginning of this year.
Specifically, the agreement will allow UMass to deepen its lung cancer screening research based on AVIEW LCS Viewer. This technology demonstrates that AI is moving beyond the application of algorithms to become a real medical tool at the point of care. “Our collaboration with UMass is an important example of how our technology can be utilized in a real-world clinical setting,” said Dr.
Jaeheon Lee, President of CorelineSoft North America. We look forward to setting a new standard for lung cancer screening and treatment, and we look forward to continuing to work with them to help provide a better healthcare experience.” On September 26, CorelineSoft was also invited to participate in an academic meeting hosted by the Cleveland Clinic in the United States.
At the meeting, CTO Jaeheon Lee will present on the AVIEW series, which has become a prominent technology in the US medical AI market. This reflects the recognition of CorelineSoft's products by medical professionals in the United States. In November, CorelineSoft will participate in the GOLD COPD International Conference 2024, the world's largest educational symposium on chronic obstructive pulmonary disease (COPD).
There, CorelineSoft will demonstrate its comprehensive chest diagnostics solutions, including the COPD diagnostic solution, which will be recognized by the global market. This agreement between UMass and CoreLineSoft goes beyond the simple supply of products and is an important step in strengthening collaboration with leading medical institutions in the United States. Going forward, the two organizations will continue to collaborate on joint research and educational programs, setting new standards in CT reading with AI.
The collaboration will also extend to various joint projects and research and development related to the treatment of lung disease, and opportunities for collaboration with other leading U.S. healthcare organizations are being explored.
.
